Medulloblastoma has been the subject of numerous genomics and transcriptomics studies that have led to this disease being subclassified into various clinically meaningful groups and to advances in understanding the biology of these subgroups, with implications for treatment.
- Paul A. Northcott
- David T. W. Jones
- Stefan M. Pfister
